Record Revenue for Carl Zeiss Meditec in Fiscal Year 2020/21

Wednesday, December 15 2021 | 14 h 41 min | Financial News, Press Release

Carl Zeiss Meditec generated revenue of approximately €1,647m in fiscal year 2020/21, corresponding to growth of +23.3% (adjusted for currency effects: +26.5%). Orders received increased even more significantly to approximately €1,731m (+29.1%, adjusted for currency effects: +32.6%). The EBIT margin was 22.7% (prior year: 13.3%). 

Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG: “We remain on a clear growth trajectory; the economic effects of the pandemic are largely behind us. At the same time, we presented a number of major innovations to our customers at the end of the fiscal year – for example, in cataract surgery and digitization.”

Both strategic business units contribute to growth

Revenue in the strategic business unit (SBU) Ophthalmic Devices increased by +26.8% in fiscal year 2020/21 (adjusted for currency effects: +29.8%), to €1,256m (prior year: €991m). In particular the business with recurring revenue from consumables, implants and services made a significant contribution to this growth. The recovery of revenue continued in the strategic business unit Microsurgery; there was an acceleration in the second half of the fiscal year in particular. Revenue increased by +13.4% (adjusted for currency effects: +17.1%) to €391m (prior year: €345m).

Clear double-digit percentage growth rates in all reporting regions

Revenue in the Americas region increased by another +16.9% to €449m (prior year: €384m) due to the further acceleration of the U.S. business – adjusted for currency effects, revenue increased by +23.9%.

Positive outlook for new fiscal year 2021/22

Due to the positive development of business and the high volume of orders, the Company is looking ahead to fiscal year 2021/22 with some optimism. Revenue is expected to grow at least to the same extent as the market. The EBIT margin in fiscal year 2021/22 is expected to be between 19-21%. In the medium term, the EBIT margin is expected to settle at a level sustainably above 20%, with the growing proportion of recurring revenue making a positive contribution. At the same time, there continues to be a need for significant strategic investments in research & development and sales & marketing.

Click HERE for the full press release.